SCHEMBL256718

SCHEMBL256718

O=C(O)c1ccc(Br)cc1Cl

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.63
CASP1 P29466 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
KDM4E B2RXH2 1/20 0.53
GLA P06280 1/20 0.53
ALDH1A1 P00352 3/20 0.50
ACLY P53396 1/20 0.50
PTPRC P08575 1/20 0.50
PTPRG P23470 1/20 0.50
SORT1 Q99523 3/20 0.49
FLT1 P17948 1/20 0.49
FLT4 P35916 1/20 0.49
KDR P35968 1/20 0.49
MYC P01106 2/20 0.49
NR4A1 P22736 2/20 0.49
TP53 P04637 1/20 0.47
DHODH Q02127 2/20 0.45
GRIK1 P39086 1/20 0.45
METAP2 P50579 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29989222 1.00 TSHR (0.63) TSHRCASP1SMN1; SMN2KDM4EGLA
SCHEMBL30249448 0.83 ALDH1A1 (0.63) KDM4EGLAALDH1A1PTPRCPTPRG
SCHEMBL30526110 0.83 FLT1 (0.49) TSHRCASP1SMN1; SMN2KDM4EGLA
SCHEMBL257466 0.83 FLT1 (0.49) TSHRCASP1SMN1; SMN2KDM4EGLA
SCHEMBL18214 0.83 ALDH1A1 (0.63) KDM4EGLAALDH1A1PTPRCPTPRG
SCHEMBL1328959 0.81 DGAT1 (0.60) TSHRCASP1SMN1; SMN2KDM4EGLA
Hydrochloric Acid SCHEMBL1631822 0.81 ALDH1A1 (0.61) KDM4EGLAALDH1A1PTPRCPTPRG
SCHEMBL10462650 0.81 ALDH1A1 (0.61) KDM4EGLAALDH1A1PTPRCPTPRG
SCHEMBL332423 0.81 ALDH1A1 (0.50) TSHRCASP1SMN1; SMN2ALDH1A1FLT1
SCHEMBL29533520 0.81 ALDH1A1 (0.50) TSHRCASP1SMN1; SMN2ALDH1A1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-110002989-B Preparation method of high-selectivity 5-bromo-2-chlorobenzoic acid 河北合佳医药科技集团股份有限公司 2021-06-22 CN claimed
CN-103008919-B Low-silver halogen-free lead-free solder paste CHENZHOU GOLD ARROW SOLDER CO LTD 2015-05-27 CN claimed
CN-103008919-A Low-silver halogen-free lead-free solder paste CHENZHOU GOLD ARROW SOLDER CO LTD 2013-04-03 CN claimed
EP-1438295-B1 AZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MERCK SERONO SA (CH) 2012-08-15 EP claimed
CN-101543943-B Leadless rosin core low-halogen no-clean scaling powder and method for preparing same YUNNAN TIN COMPANY GROUP HOLDING CO LTD 2012-07-11 CN claimed
CN-101543943-A Leadless rosin core low-halogen no-clean scaling powder and method for preparing same YUNNAN TIN COMPANY GROUP HOLDI 2009-09-30 CN claimed
EP-1216045-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS American Cynamid Company (US) 2002-06-26 EP claimed
WO-2001022969-A2 VASOPRESSIN AGONIST FORMULATION AND PROCESS AMERICAN CYNAMID COMPANY (US) 2001-04-05 WO claimed
CN-122079899-A Application of pharmaceutical composition in preparation of medicines for preventing or treating diseases related to Sirttail 7 protein 2026-05-26 CN disclosed
US-20260109676-A1 HETEROCYCLIC COMPOUNDS AND RELATED METHODS RECURSION PHARMACEUTICALS INC (US) 2026-04-23 US disclosed
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
EP-4696692-A1 CRYSTAL OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-02-18 EP disclosed
US-12528779-B2 Heterocyclic compounds and related methods RECURSION PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
CN-1085221-A Bactericide for preventing and treating plant take-all disease MONSANTO CO (US) 1994-04-13 CN disclosed
WO-1993007751-A1 FUNGICIDES FOR THE CONTROL OF TAKE-ALL DISEASE OF PLANTS MONSANTO COMPANY (US) 1993-04-29 WO disclosed
EP-0538231-A1 Fungicides for the control of take-all disease of plants MONSANTO COMPANY (US) 1993-04-21 EP disclosed
EP-0520815-A2 Method for producing ortho-alkoxybenzoic acid NIPPON CHEMICAL INDUSTRIAL COMPANY LIMITED (JP) 1992-12-30 EP disclosed
EP-0471516-A1 Tricyclic heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-19 EP disclosed
US-4959363-A HERPES VIRUS STERLING DRUG INC. (US) 1990-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109676-A1 HETEROCYCLIC COMPOUNDS AND RELATED METHODS SLC10A1, SCN1B, HSD3B2 TSHR 620/4885CASP1 2222/4885SMN1; SMN2 133/4885
US-12528779-B2 Heterocyclic compounds and related methods SLC10A1, SCN1B, NPY5R TSHR 942/4885CASP1 1168/4885SMN1; SMN2 221/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 TSHR 204/4885CASP1 1976/4885SMN1; SMN2 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.